Yahoo Suche Web Suche

  1. Combined Companies Offer Broad Portfolio of Formulation Technologies in US & EU. Adds Extensive Early-Phase Development & Analytical Services. See Details.

  2. Clinical stage biotech company revolutionizing the treatment of nerve damage. Creating innovative treatments for nervous system damage due to injury or disease

  3. There’s no limit to what we can achieve together. Small Molecule APIs, Large Molecule Biologics, API's & Intermediates, SIs, and OSDs.

Suchergebnisse

  1. Suchergebnisse:
  1. Juniper Biologics Pte Ltd, a top science-led pharmaceutical company focused on researching, developing and commercializing novel therapies.

  2. 3. Juli 2018 · Catalent, a global leader in drug delivery and development solutions, has agreed to buy Juniper Pharmaceuticals, a company with expertise in formulation development and bioavailability enhancement. The acquisition will expand Catalent's offerings and capabilities in early-phase product development and clinical-scale oral dose manufacturing.

  3. Juniper Biologics is a Singapore-based company that develops and commercialises novel therapies for oncology, rare/orphan diseases and gene therapy. It has operations in Asia, Australia, New Zealand, Middle East and Africa.

  4. Pipeline - Juniper Biologics. Pipeline for continuous benefit to patients. We’re working to identify more unmet medical needs and focus our research where it is needed most.

  5. 3. Juli 2018 · Juniper Pharmaceuticals, Inc.'s core businesses include its CRINONE ® (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical...

  6. 10. Juli 2018 · Catalent has agreed to acquire Juniper Pharmaceuticals, a Boston, Massachusetts-headquartered specialty pharmaceutical company with contract development and manufacturing services, including its Nottingham, UK-based Juniper Pharma Services Division, in a deal worth $133 million.

  7. 15. Aug. 2018 · Dive Brief: Catalent announced Tuesday that it completed its deal to acquire U.K.-based Juniper Pharmaceuticals for $11.50 per share, or a total value of $130 million. The acquisition will strengthen Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing.

  1. adesso.de wurde im letzten Monat von mehr als 10.000 Nutzern besucht

    Revolutionieren Sie die Zukunft des Gesundheitswesens mittels Digitalisierung. Mehr Erfolg mit Life Sciences Unternehmensberatung made in GermanyPharma Und Medizintechnik